Tumor necrosis factor receptor-2 signaling pathways promote survival of cancer stem-like CD133+ cells in clear cell renal carcinoma. by Bradley, John R et al.
126 |    FASEB BioAdvances. 2020;2:126–144.www.fasebbioadvances.org
Received: 25 August 2019 | Revised: 25 August 2019 | Accepted: 13 December 2019
DOI: 10.1096/fba.2019-00071  
R E S E A R C H  A R T I C L E
Tumor necrosis factor receptor-2 signaling pathways promote 
survival of cancer stem-like CD133+ cells in clear cell renal 
carcinoma
John R. Bradley1 |   Jun Wang1 |   Simon Pacey2 |   Anne Y. Warren3 |   Jordan S. Pober4 |   
Rafia S. Al-Lamki1
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original 
work is properly cited.
© 2019 The Authors.
Abbreviations: Akt, protein kinase B; AZD5363, Akt protein kinase inhibitor; BMK120, buparlisib, PI-3K inhibitor; CCK-8, cell Counting Kit-8; ccRCC, 
clear cell renal cell carcinoma; CLSM, confocal laser scanning microscopy; CSC, cancer stem-like cells; ETC, electron transport chain; Etk, endothelial/
epithelial nonreceptor tyrosine kinase; IF, immunofluorescence; JAK, Janus kinase; MFI, mean fluorescence intensity; MLKL, mixed lineage kinase-like; 
mTOR, mammalian Target of Rapamycin; PE, phycoerythrin; PI-3K, phosphatidylinositol 3-kinases; pSTAT3Ser727, phosphorylated transducer and activator of 
transcription 3 at Serine727; pSTAT3Ty705, phosphorylated transducer and activator of transcription 3 at Tyrosine705; R1TNF, TNFR1 selective mutein; 
R2TNF, TNFR2 selective mutein; ROS, reactive oxygen species; SCID, severe-combined immunodeficient mice; STAT3, signal transducer and activator of 
transcription 3; SU5408, VEGFR2 Kinase Inhibitor I; TBEA, typan bue exclusion assay; TNF, tumor necrosis factor-α; TNFR1, tumor necrosis factor receptor 
1; TNFR2, tumor necrosis factor receptor 2; TUNEL, terminal deoxynucleotidyl transferase (TdT) dUTP nick-end labeling; VEGFR2, vascular endothelial 
growth factor receptor-2; wtTNF, wild-type tumor necrosis factor; z-VAD.fmk, carbobenzoxy-valyl-alanyl-aspartyl-[O- methyl]- fluoromethylketone.
1Department of Medicine, NIHR 
Cambridge Biomedical Research Centre, 
University of Cambridge, Cambridge, UK
2Department of Oncology, NIHR 
Cambridge Biomedical Research Centre, 
University of Cambridge, Cambridge, UK
3Department of Histopathology, 
Addenbrooke's Hospital and University of 
Cambridge, Cambridge, UK
4Department of Immunobiology, Yale 
University, New Haven, CT, USA
Correspondence
Rafia S. Al-Lamki, Level 5 Department 
of Medicine, University of Cambridge, 
Cambridge CB2 0QQ, UK.
Email: rsma2@hermes.cam.ac.uk
Funding information
The work was supported by the NIHR 
Cambridge Biomedical Research Centre 
and Addenbrooke's Charitable Trust.
Abstract
Clear cell renal cell carcinoma (ccRCC) contains cancer stem-like cells (CSCs) that ex-
press CD133 (ccRCC-CD133+). CSCs are rarely in cell cycle and, as nonproliferating 
cells, resist most chemotherapeutic agents. Previously, we reported that tumor necrosis fac-
tor receptor-2 (TNFR2) signaling promotes the cell cycle entry of ccRCC-CD133+CSCs, 
rendering them susceptible to cell-cycle-dependent chemotherapeutics. Here, we describe 
a TNFR2-activated signaling pathway in ccRCC-CD133+CSCs that is required for cell sur-
vival. Wild-type (wt)TNF or R2TNF but not R1TNF (TNF muteins that selectively bind 
to TNFR2 and TNFR1) induces phosphorylation of signal transducer and activator of 
transcription 3 (STAT3) on serine727 but not tyrosine705, resulting in pSTAT3Ser727 trans-
location to and colocalization with TNFR2 in mitochondria. R2TNF signaling activates 
a kinase cascade involving the phosphorylation of VEGFR2, PI-3K, Akt, and mTORC. 
Inhibition of any of the kinases or siRNA knockdown of TNFR2 or STAT3 promotes cell 
death associated with mitochondrial morphological changes, cytochrome c release, gen-
eration of reactive oxygen species, and TUNEL+cells expressing phosphorylated mixed 
lineage kinase-like (MLKL). Pretreatment with necrostatin-1 is more protective than 
z-VAD.fmk, suggesting that most death is necroptotic and TNFR2 signaling promotes 
cell survival by preventing mitochondrial-mediated necroptosis. These data suggest that a 
TNFR2 selective agonist may offer a potential therapeutic strategy for ccRCC.
K E Y W O R D S
ccRCC, cell signaling, R1TNF, R2TNF, STAT3
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1 |  INTRODUCTION
Tumor necrosis factor-α (TNF) elicits a wide range of 
responses in almost all cell types, including cell death, 
survival, differentiation, and proliferation.1 TNF binds to 
either of two cell surface receptors; TNFR1 and TNFR2, 
which mediate distinct signaling pathways.2-4 The cell 
surface expression of each receptor is highly and inde-
pendently regulated, and may determine the dominant 
response. TNFR1 can promote cell death,2 while TNFR2 
can activate a pathway involving endothelial/epithelial 
nonreceptor tyrosine kinase (Etk), implicated in cell ad-
hesion, migration, proliferation, and survival.4 TNFR2-
mediated activation of Etk in endothelial cells or renal cell 
carcinoma cells (RCC) results in tyrosine phosphorylation 
within the cytoplasmic sequences of vascular endothelial 
growth factor receptor-2 (VEGFR2), resulting in a VEGF-
independent VEGFR2-mediated response involving acti-
vation of a PI-3K and Akt.3,5 TNFR2 may also localize 
to mitochondria,6 but its function within this organelle is 
unknown.
Emerging evidence has shown that the capacity of some 
tumors to grow and propagate resides in a small popula-
tion of slowly proliferating tumor cells referred to as can-
cer stem cells (CSCs).7 CSCs possess the characteristics 
of self-renewal and are resistant to chemotherapy and ra-
diotherapy. As they persist after cytotoxic treatment, they 
can give rise through cell division and differentiation to 
tumor cell progeny and tumor recurrence.7 Based on these 
CSCs properties, it has been proposed that their elimi-
nation can halt neoplastic expansion.8 CD133, alone or 
in combination with other molecular markers, has been 
used to isolate stem cells from normal kidney and CSCs 
from RCC.9 We refer to the CD133+CSCs in our study as 
“cancer stem-like cells” because although previous stud-
ies have reported that CD133+cells from several human 
tumors exhibit xenotransplantation potential in severe 
combined immunodeficiency (SCID) mice,10,11 isolated 
CD133+cells from human RCC tissue failed to form tu-
mors when transplanted into SCID mice but instead, these 
cells potentiate tumor engraftment when cotransplanted 
with CD133-RCC cells.11 Based on these data, we are 
uncertain if they are truly cancer stem cells capable of 
differentiation into more mature RCC cells even though 
they express stem cell markers. Significantly, CD133 ex-
pression has been suggested as a useful risk stratification 
tool in RCC.12
Signal transducers and activators of transcription 
(STAT) exist as latent, un-phosphorylated monomers 
in the cytoplasm, and transmit signals from diverse cy-
tokines and growth factors.13 STAT proteins can be 
tyrosine, serine, and/or threonine phosphorylated.14 
The best-known pathway involves the Janus kinase 
(JAK)-mediated phosphorylation of tyrosine residues, in-
ducing STAT dimerization and translocation into the nu-
cleus where phosphorylated (p)STATs act as transcription 
factors.15 For STAT3, JAK signaling is typically activated 
in response to cytokines that bind to receptors containing 
gp130, inducing the JAK-mediated phosphorylation of 
tyrosine-705.15 Nuclear phosphorylation of STAT3 tyro-
sine-Y705 (pSTAT3Ty705) promotes cell growth and many 
malignancies exhibit constitutive pSTAT3Ty705. Neither 
TNF receptor has been linked to this response. Recent 
evidence has shown that phosphorylation of STAT3 on 
serine-727 (pSTAT3Ser727) also contributes to, or is suf-
ficient for, the growth and transformation of malignant 
cells.16,17 pSTAT3Ser727 has been identified in mitochon-
dria,16-18 and pSTAT3Ser727 but not pSTAT3Ty705 is crucial 
for the optimal activity of complexes of the electron trans-
port chain (ETC) in mitochondria where it protects cells 
against the stress-induced generation of reactive oxygen 
species (ROS).19,20
We recently reported that selective ligation of TNFR2 
can drive the cell-cycle entry of CD133+CSCs isolated 
from ccRCC (ccRCC-CD133+CSCs), rendering them sensi-
tive to killing by a chemotherapeutic agent.21 The current 
investigation was initiated to understand the mechanism 
through which TNFR2 acts. We describe an unexpected 
link between TNFR2 and STAT3 signaling in ccRCC-
CSCs that express CD133 and other stem cell markers. 
We report that in CD133+CSCs, TNFR2 signaling through 
the VEGFR2/Phosphoinositide 3-kinase (PI-3K)/Protein 
kinase-B (Akt)/Mechanistic Target of Rapamycin com-
plex (mTORC) pathway induces pSTAT3Ser727 that colo-
calizes with TNFR2 in mitochondria. Disruption of this 
pathway results in mitochondrial instability, mitochondrial 
outer membrane permeabilization, generation of ROS, and 
necroptotic cell death.
2 |  MATERIALS AND METHODS
2.1 | Reagents/Antibodies
Antibodies and reagents used were anti-CD133/1-W6B3C1 
(cat~130-092-395) (Miltenyi Biotec Ltd, Surrey, UK), anti-
CD133 (cat~E90032)(Source Bioscience, Nottingham, 
UK), anti-STAT3 (phospho-Ty705) [EP2147Y] (ab76315), 
anti-STAT3 (phospho-Ser727) (ab131103), anti-PI-3K-
p110β [epr5515(2)](cat~ab151549), anti-Akt (phospho-
Thr308) (cat~ab8933), anti-Akt (phospho-Ser473)[EP2109Y]
(cat~ab81283), anti-mTOR (phospho-Ser2448)(cat~ab118815), 
anti-VEGFR2 (phospho-Y1054-1059)(cat~ab5473), anti-
human TNF Receptor II [EPR1653] (cat~ab109322), 
anti-phospho-Histone H3S10 antibodies (cat~ab14955 and 
cat~ab5176), anti-phospho-MLKLSer358 (cat~ab187091) 
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and N-Acetyl-L-Cysteine (NAC, cat~ab143032), and phos-
phorylated JAK-1, −2, and −3 (cat~ab32101, ab61102; 
ab138005; Abcam). Rabbit anti-human mitochondria 
(MAB3598) (Millipore Ltd). Anti-STAT3 (cat~9132), Anti-
phospho-STAT3 Ser727 [M9C6] (cat~4113), anti-VDAC 
[D73D12] (cat~4661) and anti-cleaved caspase-3Asp175 
(cat~9661), and phycoerythrin (PE)-conjugated anti-
cleaved caspase-3p175 [5A1E] (cat~9978) (Cell Signaling 
Technology). Anti-TNF RII/TNFRSF1B (cat~MAB226-PB) 
(R&D Systems). Anti-SSEA-4 [MC81370] (cat~MA1021X) 
(Perbio Science Ltd). Anti-Nanog (cat~MCA5657T) (Bio-
Rad Laboratories Ltd). Anti-cytochrome c (cat~556432), 
PE-conjugated: anti-phospho-STAT3S727 (cat~558557), 
anti-mTORSer2448 (cat~563489) and anti-phospho-AktThreo-
nine308 (cat~558275)(BD Pharmingen). MitoTracker™Red 
CMXRos (cat~M7512), Hoechst-33342 (cat~62249), 
8-well Nunc™ Lab-Tek™ II Chamber Slides™ System 
(cat~154526PK), Gibco™ Opti-MEM™ I Reduced Serum 
Medium (cat~31985062), CellROX™Green (cat~C10492), 
BD Cytofix™ (cat~554655), and BD  Phosflow Perm 
Buffer II (cat~558050) (Thermofisher Scientific). Tissue 
Dissociation Kit (cat~130-095-929), MS columns (cat~130-
042-201), and C-Tubes (cat~130-093-237) (Miltenyi 
Biotec). z-VAD.fmk (cat~G7231; Promega Madison). 
VEGFR2 Kinase Inhibitor I (SU5408, cat~ab145888), 
Ku-0063794 (mTORC1/2 inhibitor) (cat~13597) (Cayman 
Chemical), Akt inhibitor (AZD5363) (cat~S8019), and 
PI-3K inhibitor (BMK120, Buparlisib) (cat~S2247)( 
Selleckchem). wtTNF (cat~201-TA-020; R&D Systems), 
TNFR1 and TNFR2-muteins (R1TNF and R2TNF) 3,4,21 
are a generous gift from Prof Peter Vandenabeele (Ghent, 
Belgium). For TNFR1 the point mutation is R32W and for 
TNFR2 is D143N.22 Necrostatin-1 (Nec-1, cat~N9037) 
(Sigma-Aldrich, Dorset, UK), TUNEL-label (dUTP−FITC) 
(cat~11767291910), Terminal transferase enzyme (TdT) 
(cat~03333566001), Cell Counting Kit-8 (cat~96992), and 
trypan blue dye (cat~T6146) (Sigma-Aldrich, Dorset, UK).
2.2 | Collection of tissue samples
Samples of ccRCC and adjacent nontumor kidney tissue (NK) 
(n = 10) were collected from radical nephrectomies removed 
for tumor resection through Cambridge University Hospital 
Tissue Bank. Written informed consent was obtained from all 
patients in accordance with the local Ethics Committee. ccRCC 
samples were graded on hematoxylin and eosin (H&E) stained 
sections by AYW according to the World Health Organisation/
International Society of Urological  Pathology  (ISUP).23 All 
samples were immersed in tissue culture medium as previously 
described 2 and processed for the isolation of stem cells from 
ccRCC (ccRCCCD133+ CSCs) and NK (NK-CD133+cells) and 
short-term organ culture experiments.2
2.3 | ccRCC and NK organ cultures
As previously described,4 duplicate <1 mm3 fragments of 
ccRCC (grade 2) and NK were maintained in organ culture 
in 96-well plates and either left in medium alone (UT) or 
pretreated with wild-type (wt)TNF (10 ng/mL) or R1TNF or 
R2TNF (1 μg/mL) for 3h at 37°C. As previously reported,4 
TNF does not induce any significant effect in organ cul-
tures at <3 hours with a longer incubation time resulting in 
rapid deterioration of tissue quality. About 5 μmol/L thick 
formaldehyde fixed paraffin-wax embedded sections was 
then prepared for subsequent experiments.
2.4 | Isolation and characterization of 
ccRCC-CD133+ CSCs and NK-CD133+ cells
CD133+cells from ccRCC and NK tissue were isolated 
as previously described.21 In brief, ~2  cm2 tissue pieces 
were digested into single-cell suspension using Miltenyi 
Tissue Dissociation Kit on a GentleMACs Disassociator 
and incubated for 30min (37°C) on a MACsMix rotator, 
then passed through a 40 μm strainer. Cells were cultured 
in nondifferentiating medium.11 ccRCC-CD133+CSCs and 
NKCD133+ cells were isolated using immunobeads conju-
gated to CD133 antibody and passed through the LS col-
umn on MiniMACS Separator.24 Both magnetically labeled 
cells (CD133+cells) and unlabelled cells (CD133-cells) 
were collected. A yield of ~1 × 104 cells/tissue sample was 
seeded in T25 flasks and grown to confluence for subse-
quent experiments.
2.5 | RNA interference (siRNA)
TNFR2 and STAT3 expression were knocked down in ccRC-
CCD133+ CSCs and NKCD133+ cells using small interfering 
RNA (siRNA) (Horizon Discovery Ltd). These included 
human ON-TARGETplus™ TNFRSF1B siRNAs (10 nMol-
set of four individual, cat~J-003934-05-0002, J-003934-
06-0002, J-003934-07-0002, J-003934-08-0002), human 
ON-TARGETplus™TNFRSF1A (10 nMol-set of four indi-
vidual, cat~L-005197-00-0005), and ON-TARGETplus™ 
nontargeting human siRNA (NTsiRNA; cat~D-001810-01-
05), which does not target any known mammalian genes, 
as negative control, set of three human individual Stealth 
STAT3siRNAs (20nMol, cat~HSS110279, HSS186130, 
HSS186131) (Invitrogen). siRNA complexes (50  nmol/L) 
were transfected using DharmaFECT Duo (5 μmol/L, cat~T-
2010-03)(Horizon Discovery) in Opti-MEM™ Reduced 
Serum Medium (Thermofisher Scientific), respectively, for 
24, 48, and 72h (37°C) and knockdown efficiency deter-
mined by immunoblotting.
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2.6 | Immunofluorescence (IF) and confocal 
laser scanning microscopy (CLSM)
Immunostaining was carried out as previously described.21 
For organ cultures, deparaffinized sections were exposed to 
high-pressure antigen retrieval before incubation with anti-
pSTAT3Ser727, -CD133 or -TNFR2 (1:100) overnight (4°C). 
For cells, 8-well slide chambers were permeabilized at 
−20°C in cold methanol (4 minutes) before incubation with 
anti-CD133 alone or -anti-SSAE and -Nanog (1:100 dilu-
tion) overnight (4°C). In parallel, cells treated with wtTNF 
(10  ng/mL), R1TNF, R2TNF (1  μg/mL) or left UT for 
30 minutes (37°C) were incubation with anti-pSTAT3Ser727 
and -CD133 or -TNFR2; anti-CD133 and phosphorylated-
VEGFR2Y1059, -PI-3K110β, -AktThr308 or -mTORSer2448. 
Following TNF treatment, some cultures were incubated 
with MitoTracker™Red CMXRos (5 μmol/L)(detects mito-
chondria in live cells) for 15 minutes (37°C) then fixed in cold 
methanol prior to immunostaining for TNFR2 or pSTAT-
3Ser727. For siRNA transfected cells, MitoTracker™Red 
CMXRos was followed by incubation with anti-Cy-
tochrome-c antibody. This was followed by specified-spe-
cific secondary antibody-conjugated to Northern Light-498 
or −557 plus Hoechst 333 342 (1 μg/mL) for nuclei detec-
tion for 1  hour (1:100), mounted in VectaShield (Vector 
Laboratories) before viewing on a TCS-SPE CLSM (Leica 
Microsystems). Isotype-specific sera was used as a negative 
control. Image for each fluorophore was acquired sequen-
tially using the same constant acquisition time and set-
tings rather than simultaneously to avoid crosstalk between 
channels. Images were processed using Adobe Photoshop 
CS6 software and the Mean Fluorescence Intensity (MFI) 
minus the background signal was quantified using Image 
J 1.49v. For TNFR2/pSTAT3Ser727, double-positive cells 
were counted in random 10 high power fields of view in an 
unbiased manner and presented as the percentage using the 
formulae (double-positive cells/total cells ×100).
2.7 | Flow cytometry
About 1x105cells/well were treated with wtTNF R1TNF, 
R2TNF or left UT for 30  minutes (37°C), fixed in BD 
Cytofix™ (room temperature) and permeabilized in 
BD Phosflow Perm Buffer II (4°C) for 10 minutes in each, 
then incubated with PE-conjugated antibody to -CD133, 
-TNFR2, -pSTAT3Ser727, -VEGFR2Y1059, -PI-3K110β, 
-AktThr308 or -mTORSer2448 for 15  minutes (room tempera-
ture) and examined on BD FACSCanto™II. Parallel cultures 
were pretreated for 1h (37°C) with specific inhibitors to these 
phosphorylated proteins: [SU5408 (VEGFR2)(1  μmol/L), 
BMK120 (PI-3K)(4 μmol/L), AZD5363 (Akt) (0.8 μmol/L), 
and Ku-0063794 (mTORC1/2] (5  μmol/L)25-29 prior to 
treatment with wtTNF, R1TNF or R2TNF or left in vehicle 
(dimethyl sulfoxide, DMSO; <0.2%) referred, herein, as UT. 
The inhibitors were diluted in DMSO to a stock concentra-
tion of 10mm and stored at −20°C. The working concentra-
tion for each inhibitor was determined using a dose-response 
curve and controls included treatment of cells with inhibitors 
alone to determine any nontarget effects. A total of 20 000 
events per sample were acquired and the data were analyzed 
with FlowJo v10 software.
2.8 | Immunoblotting
About 0.5x106 cells/well were treated with wtTNF or UT 
for 30  minutes (37°C) than lysed in RIPA buffer (Sigma 
Aldrich). About 50  μg protein separated by SDS-PAGE 
was blotted on nitrocellulose membrane and incubated 
with anti-total STAT3 or -pSTAT3Ser727 overnight (4°C) 
(1:1000). Blots were incubated with species-specific HRP-
conjugated secondary antibodies for 1h (room temperature) 
(Dakocytomation) and protein bands detected by Super 
Signal West Pico Chemiluminescent substrate kit (Thermo 
Fisher Scientific) and visualized using ChemDoc Universal 
Hood III Imaging System (Bio-Rad Laboratories Ltd). 
β-Actin was used as a loading control. Cells were processed 
in a similar manner following siRNA transfection.
2.9 | Cell viability and cell death assays
Cell counting kit-8 (CCK-8) and Trypan Blue Dye Exclusion 
(TBDE) assays were used to analyze cell viability follow-
ing siRNA transfection targeting TNFR2, STAT3, NTsiRNA 
plus DharmaFECT-Duo or left UT in Opti-MEM™ Reduced 
Serum Medium for 24, 48, and 72 hours (37°C). Following 
siRNA transfection, some cells were posttreated with wtTNF, 
R1TNF, and R2TNF for 30 minutes (37°C) then CCK-8 rea-
gent (10 μL) was added to each well for 4h (37°C) and the 
absorbance (OD) was measured at 450nm on Infinite M200 
PRO Microplate Reader (Tecan). Cell viability was calcu-
lated using the formula (OD of test samples/OD of control 
×100). Parallel cultures were stained with 0.2% Trypan Blue 
Dye, viable/nonviable cells counted using a hemocytometer, 
and percentage cytotoxicity calculated using the formula 
(Live or Dead cell count/Total cells ×100).
TUNEL (Terminal deoxynucleotidyl transferase (TdT) 
dUTP nick-end labeling) was used to detect cell death as 
previously described.2,4 Following siRNA transfection 
for 24, 48, and 72 hours, cells were treated with wtTNF, 
R1TNF, R2TNF or left UT for 30  minutes (37°C) then 
fixed in cold methanol for 4  minutes (−20°C) and incu-
bated in a mixture of TUNELFITC-label and TdT-enzyme 
(Sigma-Aldrich) for 45 minutes (37°C). This was followed 
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by Hoechst 33342 for 10 minutes (room temperature) and 
mounting in Vectashield before viewing on CLSM. The 
number of TUNEL+cells per total number of unstained vi-
able cells were counted in random 10 high power fields of 
view (x40 magnification) in an unbiased manner to deter-
mine the percentage of TUNEL+cells. To evaluate apop-
totic and necroptotic cell death, following TUNEL, cells 
were immunostained with antibody to cleaved caspase-
3Asp175 (a marker for apoptosis) or phosphorylated-MLKL 
(pMLKLSer358; a marker for necroptosis) (1:100) (4°C) 
followed by species-specific secondary antibody (1:200) 
for 1 hour (room temperature). Parallel cultures were pre-
treated with z-VAD.fmk (blocks apoptosis) (20 μmol/L) or 
Nec-1 (30 μmol/L) (blocks RIPK1, upstream of MLKL)21 
either alone or in combination for 1h prior to siRNA trans-
fection then posttreated with or without wtTNF or left UT 
for 30  minutes (37°C) prior to TUNEL and IF using the 
same antibodies.
2.10 | Transmission electron microscopy 
(TEM)
As we have previously described,30 after siRNA target-
ing TNFR2 or STAT3 or NTsiRNA or left UT for 72 hours 
(37°C), 0.5  ×  106  cells/well seeded on 6-well plates were 
fixed in 2% glutaraldehyde/2% formaldehyde, osmicated in 
1% Osmium tetroxide, dehydration in ascending series of 
ethanol solutions, and embedded in Quetol 651 resin be-
fore viewing in a Hitachi Capital (UK) PLC, Leeds West 
Yorkshire at an accelerating voltage of 80 kV.
2.11 | Mitochondria Isolation
ccRCC-CD133+CSCs (1.5  ×  106cells) were treated with 
R2TNF (1 μg/mL) or left UT for 30 minutes (37°C) then 
mitochondrial fraction was isolated using Mitochondria 
Isolation Kit (cat~89874; Thermofisher Scientific). As 
we have previously described,31 for immunogold electron 
microscopy (IGEM), cells were cells stained for TNFR2 
and pSTAT3Ser727 (1:5) overnight and further stained with 
20 and 5nm gold particles (British Biocell, Cardiff, UK) 
(1:100), followed by 2% phosphotungstic acid pH 7.0 
(30 seconds) before viewing on TEM. As we were unable 
to obtain sufficient mitochondria fraction for immunob-
lotting from ccRCC-CD133+CSCs, we used a human RCC 
immortalized cell line (RCC-26; derived from a patient 
with stage I disease) 32 Equal amount of protein (50µg) 
from mitochondria and cytosolic fraction were probed 
with anti- TNFR2, -total STAT3 or -pSTAT3Ser727 fol-
lowed by specific HRP-conjugated secondary antibodies 
prior to visualization.
2.12 | Measurement of intracellular ROS
Following siRNA transfection for 24, 48, and 72  hours 
(37°C), 5  ×  105  cells/well were processed for the meas-
urement of intracellular ROS using the cell-permeable 
CellROX™ Green33,34 (Thermo Fisher Scientific), a fluoro-
genic probe that exhibits bright-green photostable fluores-
cence upon oxidation. Negative control included pretreatment 
with N-acetylcysteine (NAC- 5 mmol/L, ROS scavenger) for 
2 hours (37°C) prior to siRNA transfection and positive con-
trol involved treatment with ROS inducer; tert-butyl hydrop-
eroxide (TBHP-5 mmol/L) for 1 hour (37°C) prior to staining. 
CellROX® Green reagent (500 nmol/L) was added to each 
well for 30 minutes (37°C) and immediately analyzed by flow 
cytometry. The fluorescent signal proportional to cellular 
ROS levels was excited by laser at 488nm and quantified on 
a BD FACS Canto II. In parallel, cells were grown on 8-well 
chamber slides, treated, and stained in a similar manner be-
fore viewing on CLSM. Images were transferred to Image 
J for quantification and the percentage of CellROX®Green 
positive cells was calculated as [positive cells/ total cells 
(×100)] in 10 random fields of view at ×40 magnification.
2.13 | Statistical analysis
Data are expressed as mean ± SEM To account for patient-
specific differences, all experiments were performed with 
organ cultures and corresponding isolated cells from at 
least three patients with triplicate samples in each assay un-
less otherwise stated. Differences between two groups were 
analyzed by Student's t test and between >2 groups by one 
or two-way analysis of variance followed by Bonferroni's 
post hoc test using GraphPad Prism v7.0 (San Diego). A P 
value <.05 was considered statistically significant.
3 |  RESULTS
3.1 | TNFR2 ligation induces pSTAT3Ser727 but 
not pSTAT3Ty705 in CD133+cells of ccRCC in situ  
in organ culture and in isolated cells
pSTAT3Ty705 associated with nuclear translocation is seen 
in many stem cells and malignancies and may play a role 
in cell proliferation. Although not known to be affected by 
TNF, we investigated if TNFR2 signaling, which is mito-
genic in ccRCC, might activate this pathway in resident 
CD133+CSCs in ccRCC organ cultures. R2TNF did not in-
crease pSTAT3Ty705 but unexpectedly increased the ex-
pression of pSTAT3Ser727 by ~10-fold as compared to UT 
controls, quantified as mean fluorescence intensity (Figure 
1A) and representative confocal images as shown in Figure 
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1B. wtTNF (not R1TNF) showed similar findings. wtTNF 
or R2TNF (not R1TNF) also induced TNFR2 expres-
sion, which colocalized with pSTAT3Ser727 in  ~  35% of 
the cells (Figure 1C,D). To further confirm the absence of 
pSTAT3Ty705 expression after TNF-treatment, organ cul-
tures were immunostained for phosphorylated JAK-1, -2, 
and -3. No signal for phosphorylated JAKs was detected in 
all cultures (data not shown).
To further study the effect of TNF, we isolated 
CD133+cells from ccRCC-(ccRCCCD133+CSCs).21 Isolated 
cells were strongly positive for CD133 and exhibited a 
stem-cell phenotype evidenced by strong immunostain-
ing for SSEA-4 and Nanog (Figure 1E,F), as previously 
reported.21 To test whether TNF phosphorylates STAT3 
in ccRCC-CD133+CSCs, cells were treated with wtTNF, 
R1TNF, and R2TNF or left UT for 30  minutes (37°C). 
Similar to ccRCC organ cultures, pSTAT3Ser727 but not 
pSTAT3Ty705 was dramatically increased by wtTNF or 
R2TNF (not R1TNF) detected by flow cytometry (Figure 
2A, quantified in 2B), confirmed by IF-confocal micros-
copy (Figure 2C), and immunoblot of whole-cell lysates 
(Figure 2D). As in ccRCC organ cultures, R2TNF-induced 
TNFR2 expression, which colocalized with pSTAT3Ser727 
in ~68% of the cells showing a cytoplasmic/granular pat-
tern of staining (Figure 2E,F).
3.2 | TNFR2-induced pSTAT3Ser727 is 
dependent upon a VEGFR2/PI-3K/Akt/
mTORC kinase cascade in ccRCC-CD133+CSCs
Our previous studies3 revealed that an important step in 
the TNFR2 signaling pathway in ccRCC linked to cell-
cycle entry involves cross-talk between phosphorylation 
of VEGFR2 at tyrosine-1059 (pVEGFR2Y1059) and cyto-
solic protein tyrosine kinase Etk. Phosphorylated VEGFR2 
then initiates a signaling cascade leading to the activation 
of Akt. In other cell types where this pathway has been 
F I G U R E  1  A-D, Organ cultures ccRCC (grade 2) were treated with either wild type-(wt)TNF, R1TNF or R2TNF or left untreated (UT-in 
media alone) for 3h at 37°C then immunostained for STAT3 serine phosphorylation (pSTAT3Ser727) or tyrosine phosphorylation (pSTAT3Ty705) 
and CD133 or with TNFR2 and pSTAT3Ser727. A, Immunofluorescence data represented as median fluorescence intensity (MFI) shows wtTNF and 
R2TNF (not R1TNF) induction of pSTAT3Ser727 expression in CD133+ CSCs (but not CD133-cells) as compared to UT control. B, Representative 
confocal images show of pSTAT3Ser727 but not pSTAT3Ty705 expression in resident CD133+CSCs (arrows), with some cells also positive for 
TNFR2 (arrows) in organ cultures treated with R2TNF. In contrast, no staining is detected in CD133-cells. C, Quantified in (D) as the percentage 
of positive cells/total cells (×100) at ×40 Mag. (Error bars represent mean ± SEM; N = 5 independent experiments of different organ cultures per 
treatment group; ***P < .001 vs UT; One way ANOVA). E, Flow cytometry analysis shows the CD133 expression in isolates of ccRCC-CD133+ 
CSCs (F). CD133+CSCs (but not CD133-cells) are positive for stem cell markers (SSEA-4 or Nanog). Blue nuclei stained with Hoechst 33342. 
(N = 3 independent experiments of three different isolates with similar results). Mag ×63; Scale bars: 100 μmol/L
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studied in detail, the first step involves the phosphoryla-
tion of a class 1 PI-3K on its 110β subunit (PI-3Kp110β). 
This activates the PI-3K p85 catalytic subunit, which phos-
phorylates phosphatidylinositol 4,5 bis-phosphate (PIP2) 
to form phosphatidylinositol 3,4,5 tris-phosphate (PIP3) in 
the inner leaflet of the plasma membrane. The generation 
of PIP3 promotes the binding of both phosphoinositide-de-
pendent kinase (PDK)-1 and Akt to the plasma membrane 
inner leaflet and when brought into proximity, PDK-1 par-
tially activates Akt through threonine 308 phosphorylation 
(AktThr308). Complete activation of Akt requires a second 
phosphorylation event at serine 473 that can be mediated by 
several different kinases, including the mechanistic target 
of rapamycin mTOR as part of mTOR complex (mTORC)2. 
However, even partial activation of Akt can promote cell 
survival.35-37 Fully activated Akt activates mTORC1 by 
phosphorylating serine-2448 (mToRSer2448),38 which is 
linked to protein synthesis and cell growth. Flow cytome-
try and IF analysis confirmed that wtTNF and R2TNF (not 
R1TNF), induce pVEGFR2Y1059, AktThr308, mToRSer2448, 
and PI-3Kp110β in ccRCC-CD133+ CSCs compared to UT 
controls (Figure 3A-D). To determine the relevance of 
this pathway for TNFR2-mediated pSTAT3Ser727 signal-
ing, cells were pretreated with specific inhibitors to these 
kinases––SU5408, BMK120, AZ5363 or Ku0063794 
(VEGFR2, PI-3K, Akt, and mTOR, respectively) and each 
decreased R2TNF-induced pSTAT3Ser727 formation by ~4-
fold in ccRCC-CD133+CSCs (Figure 4A, quantified in B). 
These data indicate a role for the ETK/VEGFR2/PI-3K/
Akt/mTORC pathway in TNFR2-mediated pSTAT3Ser727 
in ccRCC-CD133+CSCs.
3.3 | Inhibition of VEGFR2/PI-3K/Akt/
mTORC pathway induced cell death in  
ccRCC-CD133+CSCs
To confirm the involvement of the VEGFR2/PI-3K/Akt/
mTORC pathway in TNFR2-mediated pSTAT3Ser727 in 
ccRCC-CD133+CSCs, we assessed the effect of specific in-
hibitors to these kinases either alone or in combination 
with wtTNF, R1TNF or R2TNF. Cells were either left UT 
or pretreated with the inhibitors alone for 1h or with inhibi-
tors prior to TNF treatment for 30min (37°C) and subjected 
F I G U R E  2  Isolates of ccRCC-CD133+CSCs were treated with either wild type-(wt)TNF, R1TNF or R2TNF or left untreated (UT-in media 
alone) for 30 min at 37°C then immunostained for phosphorylated STAT3 serine (pSTAT3Ser727) or tyrosine (pSTAT3Ty705) and CD133 or TNFR2. 
A, Flow cytometry analysis quantified as median fluorescence intensity (MFI) show wtTNF and R2TNF (not R1TNF) induction of pSTAT3Ser727 
but not pSTAT3Ty705 as compared to UT controls (B), confirmed by confocal microscopy, (C) and a representative immunoblot of whole-cell 
lysates, relative to total STAT3 in UT cultures shown in (D). wtTNF and R2TNF also induce colocalization of TNFR2 and STAT3Ser727, quantified 
as percentage of positive cells/total number of cells (×100) at ×40 Mag (E) and, positive cells (arrows) illustrated by confocal microscopy showing 
cytoplasmic/granular pattern of staining (F). Blue nuclei stained with Hoechst 33342. Error bars represent mean ± SEM; N = 3 independent 
experiments of different isolates per treatment group. **P < .01 and ***P < .0001 vs UT; ns-not significant. One way ANOVA. Mag ×63, Scale 
bars: 100 μmol/L
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to TUNEL. The percentage of cell death was calculated 
using the formula: TUNEL-positive cells/total cells (×100) at 
×40 Mag. wtTNF and R1TNF induced cell death (Table 1). 
In the absence of inhibitors, R2TNF also induced cell death, 
but to a significantly lesser extent than wtTNF or R1TNF as 
previously reported.4 Each of the kinase inhibitors alone also 
induced cell death and this was only slightly increased by the 
addition of wtTNF, R1TNF or R2TNF. These data further 
suggest that the VEGFR2/PI-3K/Akt/mTORC pathway may 
protect from cell death.
3.4 | wtTNF and R2TNF induce the 
mitochondrial localization of TNFR2 and 
pSTAT3Ser727 in ccRCC-CD133+CSCs
While pSTAT3Ty705 is known to translocate to and act in the 
nucleus as a transcription factor, pSTAT3Ser727 exerts biolog-
ical effects in mitochondria.16,18-20 Since ligation of TNFR2 
increases the expression of TNFR2 and pSTAT3Ser727, we 
wondered if these proteins are expressed and associated 
with mitochondria in ccRCC-CD133+CSCs. To test this, cells 
treated with R2TNF for 30 minutes were postincubated with 
MitoTracker™Red for 15 minutes (37°C) and subjected to 
IF using the antibody to TNFR2 or pSTAT3Ser727. In com-
parison to UT controls, which showed a rare signal, R2TNF 
induced a marked signal for TNFR2 or pSTAT3Ser727 expres-
sion in mitochondria in ccRCC-CD133+CSCs (Figure 4C), also 
detected by IGEM (Figure 4D). As we were unable to obtain 
a sufficient number of ccRCC-CD133+CSCs for immunoblot-
ting isolated mitochondria, we isolated mitochondria from a 
ccRCC immortalized cell line (RCC-26) treated with R2TNF 
or left UT and observed that R2TNF induced the expression 
of TNFR2 and pSTAT3Ser727 (Figure 4E). These data sug-
gest that R2TNF mediates increased expression and translo-
cation of both TNFR2 and pSTAT3Ser727 to mitochondria in 
ccRCC-CD133+CSCs.
3.5 | siRNA knockdown of TNFR2 and 
STAT3 reduce cell viability and increase cell 
death in ccRCC-CD133+CSCs
To determine if TNFR2 and pSTAT3Ser727 are linked to cell 
viability in ccRCC-CD133+CSCs, TNFR2 and STAT3 protein 
expression were knocked down using siRNA. Representative 
immunoblot shows ~80%-90% knockdown efficiency at 72h 
posttransfection (Figure S1A). The effect of knockdown ex-
pression on cell viability was analyzed by CCK-8, TBED, 
and TUNEL. CCK-8 demonstrated significant suppression 
in cell viability in the absence of TNFR2 signals (41%, 13%, 
10%) and STAT3 signals (37%, 17%, 12%) compared with 
F I G U R E  3  Isolates of ccRCC-CD133+CSCs were treated with either wild type-(wt)TNF, R1TNF or R2TNF or left untreated (UT-in media 
alone) for 30 min at 37°C than immunostained for phosphorylated VEGFR2Y1059, PI-3Kp110β, AktThr308, and mTORCSeri2448. Flow cytometry 
analysis presented as mean fluorescence intensity (MFI) shows wtTNF and R2TNF (not R1TNF) induction of phosphorylation of all the four 
kinases as compared to UT controls and immunoreactive cells (arrows) are illustrated in representative confocal images (A-D). Blue nuclei stained 
with Hoechst 33342. Paired Student's t test. Error bars represent mean ± SEM N = 3 independent experiments of three different isolates with 
similar results. One way ANOVA. Mag ×63, Scale bars: 100 μmol/L
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control groups (UT and NTsiRNA––99%, 98%, 99%), more 
pronounced at 48 and 72h (+P < .0001) as compared to 24h 
(***P  <  .001), respectively. Treatment with R2TNF alone 
showed minimal effect on cell viability (95%, 81%, 85%) 
compared to control groups and did not show a significant ef-
fect in the absence of TNFR2 signals (40%, 15%, 15%), but 
did induce a minor protection in the absence of STAT3 signals 
(47%, 34%, 31%). wtTNF or R1TNF alone also caused a sig-
nificant reduction in cell viability (76%, 49%, 33%, and 75%, 
43%, 40%) but this effect was much less than that induced 
by the absence of TNFR2/STAT3 signals. Treatment with 
wtTNF in the absence of TNFR2/STAT3 signals caused only 
F I G U R E  4  Isolates of ccRCC-CD133+CSCs were treated with either R2TNF or vehicle alone (DMSO, marked as UT) for 30 min at 37°C or 
pretreated for 1h with specific inhibitors to VEGFR2 (SU5408-1 μmol/L), PI-3K (BMK120-4 μmol/L), Akt (AZ5363-0.8 μmol/L), and mTORC1/2 
(Ku0063794-5 μmol/L) prior to R2TNF. A, Flow cytometry analysis shows the R2TNF induction of pSTAT3Ser727 (blue peaks) as compared to UT 
controls (red peaks), diminished by the inhibitors, and quantified in (B). Error bars represent mean ± SEM; +P < .0001––vs UT and ***P < .0001––
vs R2TNF. C, ccRCC-CD133+CSCs incubated with MitotrackerRED for 15 min at 37°C prior to R2TNF shows the induction of TNFR2 and 
pSTAT3Ser727 expression in mitochondria (arrows) as compared to UT controls. D, Mitochondrial fraction from R2TNF-treated cultures subjected 
to immuno-gold labeling confirm mitochondria using antibody to voltage-dependent anion channel (VDAC) conjugated to 5 nm-gold (panel i) 
(arrows) and presence of TNFR2 (20nm-gold)(black arrows) and pSTAT3Ser727 (5nm-gold) (red arrows) (panel ii). E, Representative immunoblot 
of cytosolic and mitochondrial fraction from UT and R2TNF-treated RCC-immortalized cell line (RCC-26) shows TNFR2 and pSTAT3Ser727 
expression in both fractions. Blue nuclei stained with Hoechst 33342. N = 3 independent experiments of three different isolates with similar results. 
One way ANOVA. Mag ×63, Scale bars: C = 100 μmol/L, D = 200 nm
Treatment UT (%) wtTNF (%) R1TNF (%) R2TNF (%)
UT 3.60 ± 1.0 35.9 ± 2.0*** 32.6 ± 0.6*** 7.30 ± 1.4*
SU5408 59.3 ± 0.1+ 65.2 ± 0.8+ 63.5 ± 0.9+ 60.1 ± 0.1+
BMK120 57.6 ± 0.6+ 59.6 ± 0.5+ 58.26 ± 0.2+ 52.2 ± 0.1+
AZ5363 57.2 ± 0.9+ 62.3 ± 0.7+ 69.7 ± 0.8+ 61.7 ± 0.2+
Ku00063794 57.9 ± 0.3+ 63.2 ± 0.4+ 61.2 ± 0.3+ 60.2 ± 0.3+
Note: Cells were either treated with a vehicle DMSO (UT) or treated with wild-type (wt)TNF, R1TNF or 
R2TNF alone for 30 min or treated with specific kinase inhibitors alone for 1h or pretreated with inhibitors 
prior to TNF for 30min (37°C). Values represented as mean ± SEM. *P < .05,***P < .001, +P < .0001 vs UT. 
N = 3 independent experiments of 3 different isolates with similar results.
Abbreviations: AZD5363, Akt inhibitor-0.8 μmol/L; BMK120, Buparlisib, PI-3K inhibitor-4 μmol/L; DMSO, 
Dimethyl sulfoxide; Ku0063794, mTORC1/2 inhibitor-5 μmol/L; R1TNF and R2TNF, muteins selectively binds 
to TNFR1 or TNFR2-1 μg/mL; SU5408, VEGFR2 inhibitor-1 μmol/L; Wild-type TNF, (wt)TNF-10 ng/mL.
T A B L E  1  Quantification of the 
percentage of TUNEL-positive isolates 
of ccRCC-CD133+CSCs calculated as 
[TUNEL-positive/total cells (×100)] at ×40 
magnification
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a small further reduction in cell viability (Figure S1B). TBED 
showed similar findings (data not shown). We wondered if 
death in these circumstances was mediated by unopposed 
autocrine/paracrine TNF signaling via TNFR1. To address 
the role of TNFR1 more directly, cells were transfected with 
siRNA targeting TNFR139 at the same time as siRNA target-
ing TNFR2 and/or STAT3 for 48 hours, followed by treatment 
with wtTNF for 30  minutes (37°C). Immunoblot analysis 
demonstrated low levels of TNFR1 expression in control 
groups (UT and NTsiRNA), which was slightly induced by 
wtTNF than further diminished by TNFR1siRNA (Figure 
S1C). Unexpectedly, the absence of TNFR1 signals induced 
some degree of cell death (detected by TUNEL) (quantified in 
Figure 5A) but significantly less than that induced by the ab-
sence of TNFR2 or STAT3 signals either alone (¥P < .0001) 
or in combination (φP < 0.001). The absence of all three sig-
nals induced an even higher level of cell death (✤P <  .01). 
Some protection was conferred with the knockdown expres-
sion of TNFR1 in the absence of either TNFR2 or STAT3 sig-
nals alone (xP < 0.0001) but not in combination (ΨP < .001). 
The degree of cell death induced by the absence of TNFR1, 
TNFR2, and STAT3 either alone or in combination compared 
to control groups is illustrated in phase contrast micrographs 
(Figure S1D). Collectively, these data indicate that cell death 
induced by the absence of TNFR2 and of STAT3 signals are 
largely independent of TNFR1 signals.
3.6 | Mitochondria promote cell death 
induced by the absence of TNFR2 and of 
STAT3 signals in ccRCC-CD133+CSCs
Since TNFR2 signaling causes both TNFR2 and pSTAT-
3Ser727 to localize to mitochondria in ccRCC-CD133+CSCs, we 
F I G U R E  5  (A) Isolates of ccRCC-CD133+CSCs were transfected with siRNAtargeting TNFR1 for 24h or TNFR2 or STAT3 for 72 h at 
37°C or with control siRNA (nontargeting siRNA-NTsiRNA or left untreated-UT-in media alone) shows increased cell death (presented as 
percentage of TUNEL-positive cell/total cells (×100) at ×40 Mag) in the absence of all three proteins, more pronounced in the absence of TNFR2 
or STAT3 signals as compared to absence of TNFR1 or control group. Notably, the absence of TNFR1 signals in combination with the absence 
of TNFR2 or STAT3 signals confer protection by a small margin. Error bars represent mean ± SEM; **P < .01 or ***P < .001- vs control group, 
¥P < .0001- vs TNFR1siRNA; φP < 0.001- vs TNFR2siRNA or STAT3siRNA or TNFR1/TNFR2/STAT3siRNA; XP < 0.0001-vs TNFR2siRNA 
or STAT3siRNA; ΨP < 0.001-vs TNFR1siRNA; ✤P < .01- vs TNFR1/or TNFR2 and/or STAT3siRNA. B, Electron micrographs show loss of 
mitochondria cristae and distorted outer membrane in the absence of TNFR2/STAT3 signals as compared to controls (arrows) and cytochrome c 
release in cytosol (small arrows) (C) as compared to define and punctate staining in controls (arrowheads) illustrated by confocal microscopy. D, 
Flow cytometry analysis demonstrates the induction of CellROX™Green expression (Blue) in the absence of TNFR2/STAT3 signals, diminished 
by anti-oxidant N-Acetyl Cysteine (NAC) (Orange). UT controls (Red); positive control (ROS inducer Tert-butyl hydroperoxide-TBHP) (Blue). E, 
Representative confocal images of similar cultures show the nuclear signal for CellROX™Green diminished by NAC (arrows). Blue nuclei stained 
with Hoechst 33342. N = 3 independent experiments of three different isolates with similar results. Mag ×63, One way ANOVA. Scale bars: C and 
E = 100 μmol/L, B = 500nM
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examined if mitochondria played a role in cell death when 
these signals were disrupted. We first evaluated the effect 
of TNFR2 and STAT3 knockdown expression on mitochon-
drial morphology using TEM of mitochondrial fractions. In 
comparison to the control groups, the absence of TNFR2/
STAT3 signals induced noticeable changes in mitochondrial 
morphology with loss of cristae and a discontinuous outer 
membrane (Figure 5B). Mitochondria promote cell death 
through two general mechanisms, which may not be mutu-
ally exclusive. The first involves the loss of mitochondrial 
outer membrane integrity resulting in the escape of certain 
mitochondrial proteins into the cytosol. The other is medi-
ated by pathological increases in ROS generation through 
dysregulation of the mitochondrial ETC.40,41 Excessive ROS 
production may lead to apoptosis or necroptosis. We used 
surrogate assays to detect these events. To determine the loss 
of mitochondrial outer membrane integrity, we assessed the 
cytochrome c release following the knockdown expression 
of TNFR2 or STAT3 in ccRCC-CD133+CSCs. Cells were in-
cubated with MitoTracker™Red for 15 minutes (37°C) and 
immunostained using anti-cytochrome c. In comparison to 
control groups (UT and NTsiRNA), which showed a strong 
punctate staining of cytochrome c in mitochondria, the ab-
sence of TNFR2/STAT3 signals resulted in a diffuse intense 
signal in the cytoplasm (Figure 5C). These data indicate 
that mitochondrial release of proteins into the cytosol may 
contribute to cell death induced by the absence of TNFR2/
STAT3 signals. We were unable to perform subcellular frac-
tionation for the detection of cytochrome c following siRNA 
transfection of ccRCC-CD133+CSCs due to insufficient cell 
number. Next, we evaluated changes in cellular ROS levels 
using the oxidative stress-sensitive dye CellROX Green by 
flow cytometry and IF-confocal microscopy. Flow cytome-
try showed a strong signal in the absence of TNFR2/STAT3 
signals compared to control groups, significantly diminished 
by ROS scavenger NAC (Figure 5D). IF-confocal micros-
copy demonstrated a marked signal in cells with fragmented 
nuclei and distorted outer membrane, significantly less with 
NAC pretreatment by  ~7-fold in the absence of TNFR2 
signals and by ~5-fold in the absence of STAT3 signals as 
compared to the control group (Figure 5E). The addition of 
wtTNF did not induce any significant changes.
3.7 | TNFR2/STAT3 signals protect 
ccRCC-CD133+CSCs from cell death mediated 
predominantly through a caspase-independent 
necroptotic pathway
To determine the cell death mechanism induced by the ab-
sence of TNFR2/STAT3 signals, we assessed the number 
of cells containing cleaved caspase 3 (a marker of apop-
totic cell death) and serine-358 phosphorylation of mixed 
lineage kinase domain-like pseudokinase (pMLKLSer358, 
a marker of necroptotic cell death). Following siRNA tar-
geting TNFR2 and STAT3 in ccRCC-CD133+CSCs, dying 
cells identified by TUNEL were analyzed by IF using an-
tibody to cleaved caspase-3p175 and pMLKLSer358 2. Of the 
85.2%  ±  0.9% TUNEL+cells, only 18.9%  ±  0.4% were 
positive for cleaved caspase-3p175 in the absence of TNFR2 
signals and 12.5%  ±  0.9% in the absence of STAT3 sig-
nals. The addition of wtTNF in the absence of TNFR2 or 
STAT3 signals increased cell death by 21.4%  ±  0.2% and 
13.3% ± 0.3%. The addition of R1TNF showed similar find-
ings to wtTNF. wtTNF or R1TNF alone also induced the 
expression of cleaved caspase-3p175, but significantly less 
(9.5% ± 0.2% and 8.3% ± 0.5%). R2TNF induced minimal 
effect (2.1%  ±  0.1%). In comparison, 65.8%  ±  0.2% was 
positive for pMLKLSer358 in the absence of TNFR2 signals 
and 70.2% ± 0.4% in the absence of STAT3 signals slightly 
increased by wtTNF (+TNFR2siRNA 66.1%  ±  0.5% and 
+STAT3siRNA 75.1% ± 1.4%). wtTNF or R1TNF alone in-
duced pMLKLSer358 but significantly less (16.8% ± 1.2% and 
18.2% ± 0.4%).
Next, we utilized specific inhibitors to confirm the involve-
ment of cleaved caspase-3p175 and pMLKLSer358 on cell death 
induced by the absence of TNFR2/STAT3 signals. Cultures 
were treated with z-VAD.fmk (a pan-caspase inhibitor) or ne-
crostatin-1 (Nec-1; an inhibitor of RIPK1 kinase activity),2 
either alone or in combination, or prior to siRNA targeting 
TNFR2 and STAT3 (±wtTNF) and cell death quantified by 
TUNEL. zVAD.fmk conferred partial protection ~2-fold from 
cell death induced by the absence of TNFR2/STAT3 signals, 
more attenuated by Nec-1 ~ 5-fold, with an additive effect with 
a combination of the inhibitors ~7-fold (Figure S2A,B). The 
addition of wtTNF did not induce an additive effect. These data 
imply that TNFR2 and STAT3 signals are important in sus-
taining cell viability and that their absence induces cell death 
predominantly via a caspase-independent pathway in ccRCC-
CD133+CSCs, consistent with our previous report.21
3.8 | Comparison between CD133+ cells 
from ccRCC and NK
In a final series of experiments, we compared responses 
of CD133+ CSCs in ccRCC and normal kidney stem cells 
(NK-CD133+cells) in organ cultures and their isolated coun-
terparts. As shown in Table 2, NK-CD133+cells show similar 
but less marked responses to wtTNF and TNFR2. Resident 
NK-CD133+cells in organ cultures induced significantly less 
expression of pSTAT3Ser727 (~2-fold) in response to wtTNF 
and R2TNF as compared to in CD133+CSCs in cRCC organ 
cultures (Figure S3A,B). Moreover, the number of cells 
that responded to TNFR2 by colocalization of TNFR2 and 
pSTAT3Ser727 were significantly less (~15%) as compared 
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to CD133+CSCs in ccRCC organ cultures (~35%) (Figure 
S3C,D). Like their counterparts, isolated NK-CD133+ cells 
expressed stem-cell markers (Figure S3E,F) and responded 
to TNFR2 by the induction of pSTAT3Ser727 (Figure S4A-
D) and its colocalization with TNFR2 but the percent-
age of immunoreactive cells was significantly less (~8% 
vs ~70% in ccRCC-CD133+CSCs) (Figure 4E, quantified in 
4F). However, in contrast to ccRCC-CD133+CSCs, activa-
tion of the kinase cascade appears to predominantly involve 
Akt and mTOR, with less activation of VEGFR2 and PI3K 
(Figure S5A-D) and specific inhibition of Akt and mTOR 
resulted in a diminished R2TNF-mediated pSTAT3Ser727 
induction (Figure S6A,B) and cell death but significantly 
less (~2-fold) compared to that observed in ccRCC-
CD133+CSCs (Table S1). Ligation of TNFR2 also induces the 
mitochondrial translocation of TNFR2 and STAT3 in NK-
CD133+cells (Figure S6C).
The absence of TNFR2/STAT3 signals in NK-CD133+cells 
also suppressed cell viability and induced cell death but sig-
nificantly less than in ccRCC-CD133+CSCs (~3-fold vs ~9-
fold) (Figure S7A,B). Knockdown of TNFR1 signals also 
induced a small degree of cell death in NK-CD133+cells and as 
in ccRCC-CD133+CSCs, absence of all three signals induced 
an even higher level of cell death but significantly less(~2-
fold) than in ccRCC-CD133+CSCs (Figure S7C). Similarly, the 
majority of TUNEL+ cells were positive for pMLKLSer358 
(Figure S8A, quantified in Table 3), with cell death sig-
nificantly attenuated by Nec-1, more so by its combination 
with z-VAD.fmk (quantified in Table 4). Cell death in NK-
CD133+cells was also associated with cytochrome c release 
T A B L E  2  Comparison between CD133+ cells in short term organ cultures and isolates from normal kidney (NK) and clear cell renal 
carcinoma (ccRCC)
NK organ cultures ccRCC organ cultures
% Immuno-positive cells
Treatment pSTAT3Ser727 pSTAT3Ty705 TNFR2/pSTAT3Ser727 pSTAT3Ser727 pSTAT3Ty705 TNFR2/pSTAT3Ser727
UT 1.0 ± 0.1 1.0 ± 0.2 1.0 ± 0.1 6.0 ± 0.2 1.0 ± 0.2 3.2 ± 0.1
wtTNF 13 ± 0.2 1.0 ± 0.2 15.0±0.1 46 ± 0.4 1.0 ± 0.2 35 ± 0.6
R1TNF 2.0 ± 0.5 1.0 ± 0.4 3.0 ± 0.1 7.0 ± 0.2 1.0 ± 0.3 3.1 ± 0.2
R2TNF 12.1 ± 0.1 1.0 ± 0.3 13.1 ± 0.2 44.1 ± 0.2 1.0 ± 0.2 33.1 ± 0.3
NK-CD133+cells ccRCC-CD133+CSCs
Median fluorescence intensity Immuno-positive cells Median Fluorescence Intensity
Immuno-positive 
cells
  pSTAT3Ser727 pSTAT3Ty705 TNFR2/pSTAT3Ser727 pSTAT3Ser727 pSTAT3Ty705
TNFR2/
pSTAT3Ser727
UT 100 100 1.0 ± 0.1 100 100 1.5 ± 0.1
wtTNF 201 ± 2.0 101 ± 0.3 8.1 ± 0.5 695 ± 0.3 104.1 ± 0.5 70.2 ± 0.3
R1TNF 87.2 ± 0.1 101 ± 0.1 1.0 ± 0.3 115 ± 1.2 100.5 ± 0.1 3.3 ± 0.4
R2TNF 219 ± 0.8 101 ± 0.1 7.5 ± 0.1 772 ± 1.4 102.7 ± 0.2 68.3 ± 0.2
Median fluorescence intensity
  pVEGFR2pY1059 PI-3Kp110β pAkt-Thr308 pmTORCSer2448 pVEGFR2pY1059 PI-3Kp110β pAkt-Thr308 pmTORCSer2448
UT 100 100 100 100 100 100 100 100
wtTNF 101 104 ± 0.1 150 ± 0.3 210 ± 0.2 236 ± 2.6 350 ± 0.5 310 ± 0.7 330 ± 1.5
R1TNF 102 100 110 ± 0.3 110 ± 0.1 103 ± 0.1 101 ± 0.1 110 ± 0.2 101 ± 0.1
R2TNF 105 106 ± 0.2 220 ± 1.8 230 ± 0.1 231 ± 1.5 330 ± 1.7 380 ± 0.9 350 ± 0.8
Note: Wild-type (wt)TNF and R2TNF (but not R1TNF) induce pSTAT3Ser727, but not pSTAT3Ty705 and, colocalization of TNFR2 and pSTAT3Ser727. wtTNF and 
R2TNF-mediated pSTAT3Ser727 occurs via the activation of VEGFR2, PI3-K, Akt, and mTORC as specific inhibition of these kinases result in a diminished expression 
of TNF-mediated pSTAT3Ser727, more pronounced in CD133+cells from ccRCC as compared to NK.
Percentage represents mean ± SEM, n = 3 samples and each treatment group.
Abbreviations: NTsiRNA, nontargeting siRNA; pAktThr308, phosphorylated Protein B at Threonine 308; PI-3Kp100β, phosphorylated phosphoinositide 3-kinases at 
110β; pmTORCSer2448, phosphorylated mammalian Target of Rapamycin at serine 2448; pSTAT3Ser727, phosphorylated STAT3 serine 727; pSTAT3Ty705, phosphor-
ylated STAT3 tyrosine 705; pVEGFR2Y1059, phosphorylated-vascular growth factor receptor 2 at Tyrosine 1059; R1TNF and R2TNF, mutein selectively binds to 
TNFR1 or TNFR2 −1 μg/mL; STAT3siRNA, siRNA targeting STAT3; TNFR2siRNA, siRNA targeting TNFR2; UT, untreated - in media alone; Wild type, (wt)TNF 
−10 ng/mL.
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in the cytosol and generation of ROS but the frequency/
intensity of these factors was notably less than in ccRCC-
CD133+CSCs (Figures S8B-D, quantified in Table 5). In sum-
mary, NK-CD133+cells show similar but less marked responses 
to TNFR2. The percentage of NK-CD133+cells that respond by 
colocalization of TNFR2 and pSTAT3Ser727 is significantly 
less and activation of the kinase cascade appears to pre-
dominantly involve Akt and mTOR, with less activation of 
VEGFR2 and PI-3K than in ccRCC-CD133+CSCs (Figure 2). 
Ligation of TNFR2 also induces mitochondrial translocation 
T A B L E  3  Quantification of percentage of TUNEL+CD133+cells from normal kidney (NK-CD133+cells) and clear cell renal carcinoma 
(ccRCC-CD133+CSCs) alone or in combination with immunostaining for pMLKLSer358 or Clv-Casp3p175 following treatment with wtTNF, R1TNF, 
or R2TNF (30 min/37°C) or with siRNA targeting TNFR2, STAT3, or negative controls (UT and NTsiRNA) at 72h (37°C)
Treatment
NK-CD133+Cells (%) ccRCC-CD133+CSCs (%)
TUNEL+ Clv-Casp3p175+ pMLKLSer358+ TUNEL+ Clv-Casp3 p175+ pMLKLSer358+
UT 0.1 ± 0.1 0.1 ± 0.1 0.1 ± 0.1 3.0 ± 0.2 0.1 ± 0.1 0.1 ± 0.1
wtTNF 19.2 ± 0.2 6.2 ± 0.5 15.3 ± 0.2 25.3 ± 0.3 9.5 ± 0.2 16.8 + 1.2
R1TNF 22 ± 0.3 5.2 ± 0.1 15.9 ± 0.4 26.2 ± 0.1 8.3 ± 0.5 18.2 ± 0.4
R2TNF 2.0 ± 0.1 1.9 ± 0.3 1.2 ± 0.1 3.2 ± 0.2 2.1 ± 0.1 1.9 ± 0.2
NTsiRNA 1.5 ± 0.5 0.1 ± 0.1 0.1 ± 0.1 3.2 ± 0.3 0.1 ± 0.1 0.1 ± 0.1
NTsiRNA (+T) 19.5 ± 0.2 5.8 ± 0.4 14.9 ± 0.7 24.8 ± 1.2 8.9 ± 1.1 15.2 ± 0.3
TNFR2siRNA 65.1 ± 0.4 11.9 ± 0.3 52.9 ± 0.1 85.2 ± 0.9 18.9 ± 0.4 65.8 ± 0.2
TNFR2siRNA (+T) 68.5 ± 0.7 12.3 ± 0.2 10.8 ± 0.3 87.1 ± 1.5 21.4 ± 0.2 66.1 ± 0.5
STAT33siRNA 60.1 ± 0.4 10.8 ± 0.2 49.6 ± 0.7 85.2 ± 0.5 12.5 ± 0.9 70.2 ± 0.4
STAT3siRNA (+T) 63.2 ± 0.2 9.8 ± 0.1 53.2 ± 0.4 86.3 ± 1.2 13.3 ± 0.3 75.1 ± 1.4
Note: wtTNF and R1TNF alone (but not R2TNF) induce cell death but by at smaller margin as compared to the absence of TNFR2 or STAT3 signals. No additive 
effect is seen with addition of wtTNF in the absence of TNFR2 or STAT3 signals. A higher number of TUNEL+ cells are positive for pMLKLSer358 as compared to 
Clv-Casp3p175
Percentage represents mean ± SEM, n = 3 samples and each treatment group.
Abbreviations: Clv-Casp3p175, cleaved caspase3p175; NTsiRNA, nontargeting siRNA; pMLKLSer358, phosphorylated mixed like kinase like domain at Serine358; 
R1TNF and R2TNF, wtTNF mutein selectively binds to TNFR1 or TNFR2 – 1 μg/mL; STAT3siRNA, siRNA targeting STAT3; TNFR2siRNA, siRNA targeting 
TNFR2; UT, Untreated, in media alone (1 h/37°C), T-wtTNF (10 ng/mL)
T A B L E  4  Quantification of the percentage of TUNEL+CD133+cells from normal kidney (NK-CD133+cells) and clear cell renal carcinoma 
(ccRCC-CD133+CSCs) following treatment with wtTNF, R1TNF or R2TNF alone for 30 min/37°C or with siRNA targeting TNFR2 or STAT3 or 
negative controls (UT and NTsiRNA) for 72 h/37°C (±wtTNF) and (±z-VAD-fmk and/or necrostatin-1) for 1 h/37°C prior to treatment
Treatment
NK-CD133+Cells (%) ccRCC-CD133+CSCs (%)
TUNEL+ +z +n +z/+n TUNEL+ +z +n +z/+n
UT 0.1 ± 0.1 0.1 ± 0.1 0.1 ± 0.1 0.1 ± 0.1 3.0 ± 0.2 0.7 ± 0.1 0.5 ± 0.1 0.1 ± 0.1
wtTNF 19.2 ± 0.2 9.6 ± 0.1 5.3 + 0.1 3.8 ± 0.2 25.3 ± 1.3 5.1 ± 0.1 3.42 ± 0.1 2.4 ± 0.2
R1TNF 22.5 ± 0.7 11.9 ± 0.1 4.8 ± 0.4 3.3 ± 0.1 26.2 ± 0.7 5.9 ± 0.3 6.2 ± 0.4 2.3 ± 0.1
R2TNF 2.0 ± 0.9 1.1 ± 0.1 1.0 ± 0.4 1.0 ± 1.0 3.2 ± 0.9 1.2 ± 0.3 0.2 ± 0.4 1.0 ± 0.1
NTsiRNA 1.0 ± 0.1 0.2 ± 0.1 1.1 ± 0.2 0.1 ± 0.1 2.1 ± 0.1 0.6 ± 0.4 2.2 ± 0.2 0.3 ± 0.2
NTsiRNA (+T) 18.5 ± 0.7 8.9 ± 0.5 4.8 ± 0.2 2.9 ± 0.3 24.1 ± 0.8 5.6 ± 0.4 3.6 ± 0.2 2.8 ± 0.2
TNFR2siRNA 65.2 ± 0.3 32.1 ± 0.1 12.8 ± 0.3 9.8 ± 0.8 85.2 ± 0.9 26.0 ± 0.4 13.9 + 0.3 10.9 ± 0.2
TNFR2siRNA (+T) 68.3 ± 0.2 34.3 ± 0.1 13.6 ± 0.1 9.8 ± 0.9 87.1 ± 0.3 39.1 ± 0.2 14.8 ± 0.1 12.6 ± 1.1
STAT3siRNA 60.1 ± 0.1 30.2 ± 0.1 12.2 ± 0.4 8.5 ± 0.3 83.2 ± 0.2 25.0 ± 0.1 12.2 ± 0.4 9.2 ± 0.2
STAT3siRNA (+T) 63.2 ± 0.1 31.5 ± 0.6 12.4 ± 0.5 9.6 ± 02 86.3 ± 0.2 42.1 ± 0.7 13.6 ± 0.5 10.7 ± 1.2
Note: wtTNF and R1TNF alone induce cell death, more pronounced with the absence of TNFR2 or STAT3 signals. Pretreatment with z-VAD-fmk diminishes cell 
death, attenuated by necrostatin-1 and further by a combination of the two and, significantly more in ccRCC-CD133+CSCs CSCs than in NK-CD133+cells.
Percentage represents mean ± SEM, n = 3 samples and each treatment group.
Abbreviations: n, necrostatin-1 (30 μmol/L); NTsiRNA, nontargeting siRNA; R1TNF and R2TNF, wtTNF mutein selectively binds to TNFR1 or TNFR2 - 1 μg/mL; 
STAT3siRNA, siRNA targeting STAT3; TNFR2siRNA, siRNA targeting TNFR2; UT, Untreated (in media alone), T-Wild-type (wt)TNF (10 ng/mL); z, z-VAD.fmk 
(20 μmol/L)
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of STAT3 in NK-CD133+cells, but the propensity of these cells 
to undergo mitochondrial-mediated necroptosis is signifi-
cantly reduced and inhibiting this response results in less cell 
death.
4 |  DISCUSSION
We previously reported that ligation of TNFR2 drives ccRCC-
CD133+CSCs proliferation and increases their sensitivity to cell 
cycle-dependent cytotoxicity.21 Here we elucidate the mech-
anism of the growth-promoting effect of TNFR2 signaling in 
CD133+CSCs in ccRCC using molecular, cellular, and imag-
ing techniques. We demonstrate various important findings: 
(a) TNF rapidly induces (within 30 minutes) pSTAT3Ser727, 
but not pSTAT3Ty705 and its colocalization with TNFR2 
in mitochondria, (b) TNF induces the phosphorylation of 
VEGFR2, PI-3K, Akt, and mTORC1/2 and specific inhibi-
tion of these phosphorylated proteins effectively suppresses 
TNFR2-med0iated pSTAT3Ser727 expression and increases 
cell death, (c) the absence of TNFR2/STAT3 signals causes 
cell death, mitochondrial structural changes, associated with 
translocation of cytochrome c to the cytoplasm, activation of 
cleaved caspase-3p175, phosphorylation of MLKLSer358, and 
generation of high levels of ROS, (d) cell death induced by 
the absence of TNFR2/STAT3 signals is partially inhibited 
by z-VAD.fmk, and further attenuated by Nec-1, indicating 
that cell death is predominantly necroptotic, (e) wtTNF or 
R1TNF in the absence of TNFR2/STAT3 signals further in-
crease cell death by a small margin, and (f) blocking TNFR1 
signals does not confer absolute protection from cell death 
induced by the absence of TNFR2/STAT3 signals.
Although outcomes for patients with advanced RCC have 
improved in recent years with the development of targeted 
therapies, curative treatment remains elusive. The putative 
anti-tumor activity of infliximab (anti-TNF antibody) was 
demonstrated in advanced RCC,42 but a subsequent phase I/II 
trial using a combination of infliximab and the multi-kinase 
inhibitor sorafenib showed adverse events with lack of effi-
cacy.43 Our data indicate that blocking TNFR2 may account 
T A B L E  5  Quantification of flowcytometry (top) and immunofluorescence data (bottom) of CD133+cells from normal kidney (NK-
CD133+cells) and clear cell renal carcinoma (ccRCC-CD133+CSCs) positive for CellROX® Green (marker of ROS generation) following siRNA 
targeting TNFR2 or STAT3 or negative controls (UT and NTsiRNA) for 72h/37°C or for immunostaining data treatment with wtTNF, R1TNF or 
R2TNF alone for 30min/37°C or post-treatment with wtTNF after siRNA transfection (±NAC, ROS scavenger) for 1h/37°C
Treatment
NK-CD133+cells ccRCC-CD133+CSCs
Median fluorescence intensity (CellROX® Green)
(-) NAC (+) NAC (-) NAC (+) NAC
UT 100 100 100 100
NTsiRNA 101.3 ± 0.8 100.3 ± 0.3 103.9 ± 0.2 104.2 ± 0.2
TNFR2siRNA 1231.3 ± 11.2 87.1 ± 0.5 2320.3 ± 10.6 90.1 ± 0.5
STAT3siRNA 2046.3 ± 7.2 92.4 ± 0.3 5653.6 ± 1.4 90.4 ± 0.5
% of CellROX ® green -positive cells
  (-) NAC (+) NAC (-) NAC (+) NAC
UT 0.1 ± 0.1 0.1 ± 0.1 0.3 ± 0.2 0.3 ± 0.1
wtTNF 14.1 + 2.1 3.2 ± 1.2 32.0 ± 1.3 5.7 ± 1.0
R1TNF 13.9 ± 0.9 2.6 ± 1.2 17.8 ± 0.9 5.0 ± 0.2
R2TNF 2.1 ± 0.6 1.7 ± 0.1 3.5 ± 0.3 1.2 ± 0.1
NTsiRNA 0.1 ± 0.1 0.1 ± 0.1 0.9 ± 0.1 0.1 ± 0.1
NTsiRNA (+T) 14.2 ± 0.7 3.0 ± 0.5 34.3 ± 1.2 5.3 ± 0.5
TNFR2siRNA 31.4 ± 0.3 9.1 ± 0.9 67.5 ± 0.2 10.2 ± 1.9
TNFR2siRNA (+T) 34.0 ± 1.2 9.3 ± 0.5 68.7 ± 1.6 11.1 ± 1.0
STAT3siRNA 22.1 ± 1.2 7.3 ± 0.7 56.2 ± 1.2 14.1 ± 0.2
STAT3siRNA (+T) 25.1 ± 1.9 7.1 ± 0.4 67.9 ± 1.2 15.1 ± 0.7
Note: CellROX Green staining is increased after wtTNF or R1TNF treatment, further pronounced by the absence of TNFR2 or STAT3 signals and significantly dimin-
ished by NAC.
Percentage represents mean ± SEM, n = 3 samples and each treatment group.
Abbreviations: NAC, N-Acetyl Cysteine (anti-oxidant-250 mmol/L); NTsiRNA, nontargeting siRNA; R1TNF and R2TNF, wtTNF mutein selectively binds to TNFR1 or 
TNFR2 – 1 μg/mL; STAT3siRNA, siRNA targeting STAT3; TNFR2siRNA, siRNA targeting TNFR2; UT, Untreated (in media alone); T-Wild-type (wt)TNF (10 ng/mL).
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for adverse outcomes and suggest that a TNFR2 agonist 
combined with standard chemotherapy regimens may offer 
greater efficacy.
Within the tumor microenvironment, a complex network 
of signals affects tumor initiation and progression. TNF is 
a putative autocrine and paracrine growth factor in RCC3,44 
and increases stemness via the induction of epithelial-mes-
enchymal transition.45 TNF and STAT3 can regulate plu-
ripotency.46-49 Moreover, TNF can mediate the induction 
of TNFR2 expression through STAT3 contributing to the 
tumor-promoting roles of STAT350 and regulate STAT3 
through its binding to a −1,578 STAT response element in 
the TNFR2 promoter.47 These data support the role of STAT3 
in TNFR2 signaling. We initially investigated whether 
TNF effects STAT3 phosphorylation in ccRCC-CD133+  
CSCs using a kidney tumor organ culture model and TNF 
receptor subtype-selective muteins.4 Our data demon-
strate that selective ligation of TNFR2 (not TNFR1) 
induce pSTAT3Ser727 but not pSTAT3Ty705 in resident 
CD133+CSCs in ccRCC. To study resident CD133+CSCs 
in detail we isolated them together with CD133+cells from 
nontumor zones for comparative studies. Similar to in situ 
CD133+cells, selective ligation of TNFR2 by R2TNF and 
wtTNF (but not R1TNF) induced pSTAT3Ser727 but not 
pSTAT3Ty705 in vitro in isolated CD133+cells from both 
ccRCC and NK, but the expression was more pronounced 
in ccRCC-CD133+CSCs. Our data indicate that TNFR2-
mediated pSTAT3Ser727 involves the activation of VEGFR2/
PI-3K/Akt/mTORC1/2 pathway in ccRCC-CD133+CSCs. As 
predicted, specific inhibitors of this pathway resulted in in-
creased cell death, implicating them in the TNFR2/STAT3-
mediated survival pathway. The involvement of VEGFR2 
in TNFR2 signaling is consistent with our previous report3 
and further implicates the phosphorylation of VEGFR2 in 
TNFR2-mediated survival.
The PI-3K/Akt/mTOR pathway regulates cell survival 
in a variety of tumor types including RCC and aberrant 
hyperactivation is a target for cancer therapy.51 An asso-
ciation between suppression of PI-3K/Akt/mTORC path-
way and STAT3 on inhibition of cell proliferation has 
been reported.52 Collectively, our data suggest a close 
connection between TNFR2/pSTAT3Ser727 signaling and 
VEGFR2/PI-3K/Akt/mTORC pathways in driving sur-
vival of ccRCC-CD133+CSCs. These findings may explain 
why therapy directed against these kinases have provided 
only modest survival benefits.53 Moreover, clinical ther-
apy involving adjuvant trial with receptor tyrosine kinases 
in RCC has also reported no improvement in disease-free 
survival and patients have experienced adverse events.54 
The importance of these kinases in driving the survival of 
CSCs via TNFR2 signaling and the ability of TNFR2 to 
sensitize CSCs to cytotoxic killing strongly suggest that a 
therapeutic strategy for the eradication of ccRCC would be 
cytotoxics in the absence of VEGFR2/PI-3K/Akt/mTOR 
inhibition. However, further studies will be required to de-
termine whether these kinases act in a cascade in response 
to TNFR2 signaling.
Our data showing TNFR2-mediated mitochondrial ex-
pression of TNFR2 and its association with pSTAT3Ser727 
implicate mitochondria in the survival pathway. Our EM 
data showing disrupted mitochondrial morphology in the 
absence of TNFR2/STAT3 signals further supports our line 
of thought. Previous studies have shown TNFR2 to con-
fer mitochondria-dependent cardioprotective effects via 
STAT3 activation.55 We identified a TNF-binding protein 
in the inner mitochondrial membrane that can be detected 
by a monoclonal antibody to TNFR2.6 The mechanism by 
which TNFR2 is recruited to the mitochondria is unclear. It 
may require an adaptor protein such as E3 ubiquitin ligase 
TRAF2 (TNF receptor-associated factor-2), which plays a 
key pro-survival role as an adaptor protein to transduce the 
activation of kinases and transcription factors.56 Studies 
using rat pancreatic insulin-producing INS-1E beta cell 
lines have reported that TRAF2 is required for the IFNγ-
stimulated phosphorylation of STAT3 and that TRAF2 
knockdown increases the cytokine-induced production of 
ROS.57 An earlier report has detected the TNF-induction of 
TRAF2 expression in mitochondria of RCC-26 by immu-
noblotting.58 Thus, TRAF2 may be an important mediator 
of mitochondrial TNFR2/pSTAT3Ser727 signaling. Another 
member of the TNFR2 signaling complex associated with 
mitochondria is aminopeptidase P3 (APP3).59 Further 
studies will be required to determine the role of TNFR2 
in mediating pSTAT3Ser727 localization in mitochondria 
and the role of TRAF2 and APP3 in TNFR2/STAT3 sig-
naling in ccRCC-CD133+CSCs. Alternatively, pSTAT3Ser727 
may mediate its mitochondrial translocation.60 Indeed, 
STAT3 can act as a positive or negative regulator of mito-
chondrial activity depending on specific modifications.61 
Mitochondrial pSTAT3Ser727 has been shown to be im-
portant in the growth/survival of cancer and its function 
is distinct from nuclear transcriptional regulation.17,62 
pSTAT3Ser727 but not pSTAT3Ty705 is crucial for the opti-
mal activity of complexes I/II of the ETC regulating ROS 
concentrations and metabolic function.17,20 Mitochondrial 
pSTAT3Ser727 has been shown to confer protection as a 
PS727-STAT3 dominant negative eliminates protection 
against TNF-induced mitochondrial stress and apoptosis.63 
It is, therefore, reasonable to speculate that TNFR2 signal-
ing may protect ccRCC-CD133+CSCs by modulating STAT3 
phosphorylation in mitochondria.
Using siRNA knockdown, we observed a dramatic in-
crease in cell death with the absence of TNFR2/STAT3 
signals altering mitochondrial morphology with the loss 
of cristae and outer membrane disruption, associated with 
cytosolic release of cytochrome c, generation of ROS, 
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caspase-3 cleavage, and MLKL phosphorylation. The 
specific mechanism of mitochondria in the induction of 
cell death in this context is unclear, but may involve ROS 
modulator 1 (Romo1) recruitment of B-cell lymphoma-ex-
tralarge (Bcl-X(L).64 Whatever the mechanism, these data 
support a central role for mitochondria in TNFR2/STAT3 
signaling. Additionally, increased expression of pMLK-
LSer358 and attenuation of cell death by Nec-1 as com-
pared to z-VAD.fmk strongly indicates the dominance of 
caspase-independent cell death (necroptosis), consistent 
with our previous report.2 Maintenance of normal mito-
chondrial morphology has been shown to regulate several 
aspects of mitochondrial functioning, including mitochon-
drial metabolism, ROS production, and induction of apop-
tosis.65 Mitochondrial involvement in cell death involved 
cytochrome c release and combination with cytosolic 
apoptotic protease activating factor (APAF)-1 and, in the 
presence of ATP, the formation of a complex that binds and 
promotes autocatalytic activation of the initiator caspase 
9. Activated caspase 9 proteolytically activates executioner 
caspases including caspase-3 resulting in apoptosis. Other 
released proteins, including second mitochondrial activator 
of cell death (SMAC)/Diablo, which augments caspase ac-
tivation, or apoptosis inducing factor (AIF), may also trig-
ger death.66 AIF is misnamed because, unlike cytochrome c 
and SMAC/Diablo, it acts independently of caspases66 and 
death may result from events triggered following its nuclear 
translocation and dysregulated mitochondrial function.
Importantly, we show that blocking TNFR1 signals 
confers only partial protection from cell death induced by 
the absence of TNFR2/STAT3 signals, suggesting the in-
volvement of an unknown mechanism, perhaps similar to 
that reported by Lacerda et al, where TNF’s effect on mi-
tochondria is independent of its cell surface receptors and 
F I G U R E  6  Schematic diagram of the consequences of TNFR2-mediated survival signaling in ccRCC-CD133+CSCs; selective ligation of 
TNFR2 mediates the induction of pSTAT3Ser727 through phosphorylation of VEGFR2/PI 3K/Akt/mTORC pathway leading to the survival of CSCs 
in ccRCC. Pharmacological inhibition of these phosphorylated kinases results in a diminished expression of TNF-mediated pSTAT3Ser727 formation 
and causes an increase in cell death. Furthermore, selective ligation of TNFR2 mediates the expression of TNFR2 and its association with 
pSTAT3Ser727 in mitochondria. The absence of TNFR2/STAT3 causes an increase in cell death triggering change in mitochondrial ultrastructure, 
translocation of cytochrome c to cytosol, activation of cleaved caspase 3p175, phosphorylation of MLKLSer358, and generation of ROS, which can 
be blocked by NAC. Cell death is partially inhibited by z-VAD.fmk, further attenuated by Nec-1, with an additive effect by a combination of both 
z-VAD.fmk and Nec-1, indicating the dominance of necroptotic cell death pathway
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occur via ROS generation.50 Unexpectedly, the absence of 
TNFR1 signals alone induced cytotoxic effect, albeit small 
compared to that induced by the absence of TNFR2/STAT3 
signals either alone or in combination. wtTNF or R1TNF 
did not significantly attenuate cell death induced by the 
absence of TNFR2/STAT3 signals in ccRCC-CD133+CSCs, 
indicating that they do not confer an additive effect. These 
data point to an essential role for TNFR2/STAT3 signal-
ing in the survival of CSCs independent of TNFR1 sig-
nals. Although TNFR2 is regarded to have exclusively 
pro-survival functions, whereas TNFR1 signals cell death,2 
emerging evidence indicates some overlap in TNFR2 and 
TNFR1-induced functions. Both TNF receptors are capable 
of mediating similar functions under certain circumstances, 
including cell death, proliferation, differentiation, and cy-
tokine production.67 Various factors including cell type, 
cell activation state, intracellular or extracellular environ-
ment, and whether nuclear factor kappa-B is constitutively 
expressed, may lead to a degree of functional overlap.67
In summary, we propose the model shown in Figure 6: selective 
ligation of TNFR2 mediates the induction of pSTAT3Ser727 through 
the phosphorylation of VEGFR2/PI 3K/Akt/mTORC1/2 pathway 
leading to the survival of CSCs in ccRCC. Pharmacological inhi-
bition of these phosphorylated kinases results in diminished ex-
pression of TNF-mediated pSTAT3Ser727 formation and increases 
cell death. Furthermore, selective ligation of TNFR2 increases 
TNFR2 expression and its association with pSTAT3Ser727 in mi-
tochondria. The absence of TNFR2/STAT3 increases cell death 
triggering changes in mitochondrial ultrastructure, release of cyto-
chrome c, activation of cleaved caspase 3p175, phosphorylation of 
MLKLSer358, and generation of ROS. Cell death is partially inhib-
ited by z-VAD.fmk, further attenuated by Nec-1, with an additive 
effect of a combination of both z-VAD.fmk and Nec-1, indicating 
the dominance of necroptotic cell death.
The reported insensitivity of CSCs to chemotherapy and 
radiotherapy68 suggests that current anti-cancer drugs, which 
inhibit tumor cells, may not effectively inhibit CSCs. The 
clinical relevance of targeting CSCs is supported by recent 
studies, including CD24 targeting for the treatment of pan-
creatic and colon,69 CD44 targeting for the treatment of acute 
myeloid leukemia70 and CD133 targeting for gastric and he-
patocellular cancer.71 In conclusion, our data here and from 
our previous studies21 indicate that an alternative therapeutic 
strategy for eradication of ccRCC would be to promote CSCs 
survival by a TNFR2 selective agonist in combination with 
cell-cycle dependent cytotoxic drugs. Importantly, mechanis-
tic differences between normal stem cells and cancer stem 
cells could be targeted to deplete CSCs without damaging 
normal stem cells.
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